BRISTOL MYERS SQUIBB

The article discusses the importance of SSR (Server-Side Rendering) in modern web development, emphasizing its role in improving performance and user experience.

The FDA approved a novel antipsychotic schizophrenia drug, Cobenfy, targeting cholinergic receptors to reduce side effects like weight gain and cognitive impairment. Cobenfy's monthly cost is $1,850, marking a market-driven win over government-funded research, which has yet to significantly benefit patients.

The FDA approved Cobenfy (xanomeline and trospium chloride) for schizophrenia, marking the first novel mechanism in decades, targeting M1 and M4 receptors without blocking D2. Bristol Myers Squibb's CEO highlights the potential to change the treatment paradigm.

The FDA approved Cobenfy, a new schizophrenia drug with fewer side effects than current treatments, targeting muscarinic receptors instead of dopamine. Marketed by Bristol Myers Squibb, it will be available from October at $1,850 a month, pending insurance coverage. While initial studies are promising, long-term safety and efficacy remain uncertain.

The FDA approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, marking the first in a new class targeting M1 and M2 receptors without blocking D2 receptors. Supported by the EMERGENT clinical program, Cobenfy demonstrated a statistically significant 8.4-point reduction in PANSS scores compared to placebo, with generally well-tolerated safety profile.

FDA approves Bristol Myers Squibb's Cobenfy, the first novel schizophrenia treatment in 70 years, targeting muscarinic receptors to reduce dopamine activity without typical antipsychotic side effects. Expected to launch in late October at $22,500/year, with potential peak U.S. sales of $2 billion by 2030.

Biologist with M.Sc in Biomedicine, PhD in Bioengineerings, and 20+ years in Cell & Gene Therapies (CGT) research and development, focusing on biotech, pharma, Medtech, and healthcare stocks analysis. Long position in BMY shares. Independent SA analyst adhering to Seeking Alpha’s guidelines.

Bristol-Myers Squibb's novel schizophrenia drug, Cobenfy, received FDA approval. Cobenfy, the first non-dopamine blocking treatment, aims to reduce side effects. Acquired from Karuna Therapeutics for $14 billion, the twice-daily pill will cost $1,850 monthly. BMY stock rose 4.35% to 52.30, signaling a breakout.

The FDA approved Cobenfy, the first new schizophrenia medication in decades, targeting a new neurochemical pathway via cholinergic receptors to reduce symptoms without typical dopamine-focused drug side effects like weight gain and sluggishness. Cobenfy's short-term trials showed symptom reduction, but long-term effectiveness and safety remain uncertain. The drug, priced at $1,850/month, does not carry atypical antipsychotic class warnings.